Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

NCT06269640 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT06269640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06269640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Not applicable
Overall status
Terminated
Start date
December 18, 2024
Completion date
December 23, 2024
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aortic valve stenosis, hypertrophic cardiomyopathy, left ventricular septal hypertrophy, mitral valve disease